American College of Clinical Pharmacy ®

Tuesday, February 8, 2022
Available for 4.00 hours of CPE credit
Activity Number: 0217-0000-22-007-H01-P

Faculty: Erika J. Ernst, Pharm.D., FCCP, BCIDP Associate Professor, Department of Pharmacy Practice and Science, University of Iowa College of Pharmacy; Clinical Pharmacy Specialist, infectious diseases, University of Iowa Hospitals and Clinics, Iowa City, Iowa View Biography	Ernst
Faculty: Michael B. Kays, Pharm.D., FCCP, BCIDP Associate Professor of Pharmacy Practice, Purdue University College of Pharmacy; Clinical Specialist, Infectious Diseases at IU Health, Methodist Hospital; Adjunct Associate Professor of Medicine, Indiana University School of Medicine, Indianapolis, Indiana View Biography	Kays

Summarize emerging resistance threats.
Recognize current and emerging resistance mechanisms.
Use and interpret antibiogram information for resistance trends and clinical decisions.

Assess the incidence and risk factors for multidrug-resistant gram-negative infections, including extended-spectrum beta-lactamase-producing organisms, carbapenem-resistant Enterobacterales, multidrug-resistant Pseudomonas aeruginosa, and carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia.
Describe and evaluate the role of rapid diagnostic tests to aid in the identification and diagnosis of gram-negative infections and discuss how rapid diagnostic tests may improve clinical outcomes.
Describe and analyze in vitro activity, dosing regimens, and clinical data for current and emerging treatment options for multidrug-resistant gram-negative infections.

Evaluate the incidence and risk factors for resistant gram-positive infections, including methicillin-resistant Staphylococcus aureus and Vancomycin Resistant Enterococci.
Describe how rapid diagnostic tests are used in the identification and diagnosis of gram-positive infections, including their potential impact on clinical outcomes.
Analyze literature and clinical trials for current and emerging treatment options for multidrug-resistant gram-positive infections.

Assess the incidence and risk factors for multidrug-resistant tuberculosis.
Describe and evaluate the pros and cons of rapid diagnostic tests to aid in identification of patients infected with multidrug-resistant tuberculosis.
Critically evaluate therapeutic options and recent guidelines for treatment of multidrug-resistant tuberculosis and develop a treatment plan for a patient with multidrug-resistant tuberculosis.

Back to Schedule

Back to Symposium